- Home
- SRFM vs TTRX Comparison
SRFM vs TTRX Comparison
Compare SRFM & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRFM | TTRX |
|---|---|---|
| Founded | 2011 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 123.3M | 116.0M |
| IPO Year | 2023 | N/A |
Fundamental Metrics
Financial Performance| Metric | SRFM | TTRX |
|---|---|---|
| Price | $1.16 | $3.28 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $3.25 | ★ $8.00 |
| AVG Volume (30 Days) | ★ 2.2M | 20.0K |
| Earning Date | 05-12-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 45.69 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $106,557,000.00 | N/A |
| Revenue This Year | $25.90 | N/A |
| Revenue Next Year | $20.72 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $2.57 |
| 52 Week High | $9.35 | $5.98 |
Technical Indicators
Market Signals| Indicator | SRFM | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 31.94 | 43.46 |
| Support Level | $1.04 | $2.64 |
| Resistance Level | $2.16 | $3.73 |
| Average True Range (ATR) | 0.10 | 0.21 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 25.93 | 43.08 |
Price Performance
Historical ComparisonAbout SRFM Surf Air Mobility Inc.
Surf Air Mobility Inc provides a regional air mobility platform to connect communities sustainably. The company is an electric aviation and air travel company expanding the category of regional air travel and reinventing flying through electrification. The company is building a regional air mobility ecosystem to sustainably connect the world's communities. It generates revenue through air mobility services.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.